Open AccessDose Response and Pharmacokinetics of Tofacitinib (CP‐690,550), an Oral Janus Kinase Inhibitor, in the Treatment of Chronic Plaque Psoriasis
Author(s) -
Tan H,
Gupta P,
Harness J,
Wolk R,
Chapel S,
Menter A,
Strober B,
Langley RG,
Krishnaswami S,
Papp KA
Publication year - 2013
Publication title -
cpt: pharmacometrics and systems pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.53
H-Index - 37
ISSN - 2163-8306
DOI - 10.1038/psp.2013.22
Subject(s) - tofacitinib , janus kinase inhibitor , medicine , psoriasis , pharmacokinetics , clinical trial , placebo , population , pharmacology , plaque psoriasis , covariate , dosing , dermatology , rheumatoid arthritis , statistics , pathology , mathematics , alternative medicine , environmental health
Longitudinal nonlinear mixed effects modeling was used to characterize the dose–response profile of tofacitinib using data from a placebo‐controlled dose‐ranging study, where tofacitinib 2, 5, and 15 mg twice daily (b.i.d.) were evaluated for plaque psoriasis treatment. Bayesian estimation was applied with prior information derived from the literature: nonclinical and clinical data in psoriasis, as well as other indications. The probability to achieve a certain target effect associated with a given dose was calculated from the posterior samples. On the basis of these probabilities along with safety considerations, tofacitinib 5 and 10 mg b.i.d. were selected for further testing in confirmatory phase III clinical trials. Pharmacokinetics in patients with psoriasis was characterized using a population‐based modeling approach, and body weight was identified as an important covariate. A subgroup analysis suggested reduced efficacy of tofacitinib with increasing body weight; however, it is unclear whether this trend could be explained by systemic exposure alone. CPT: Pharmacometrics & Systems Pharmacology (2013) 2, e44; doi: 10.1038/psp.2013.22 ; advance online publication 22 May 2013